Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 18/20 | 0.78 |
| ▸ | AKR1C2 | P52895 | 18/20 | 0.78 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL293867 | 0.88 | AKR1C3 (1.00) | AKR1C3AKR1C2 | |
| SCHEMBL295164 | 0.87 | AKR1C3 (0.81) | AKR1C3AKR1C2 | |
| SCHEMBL846875 | 0.87 | AKR1C3 (0.81) | AKR1C3AKR1C2 | |
| SCHEMBL296153 | 0.84 | AKR1C3 (0.76) | AKR1C3AKR1C2 | |
| SCHEMBL6443532 | 0.82 | MEN1 (0.72) | — | |
| SCHEMBL28357281 | 0.81 | SIRT2 (0.75) | AKR1C3AKR1C2PDE4B | |
| SCHEMBL1724047 | 0.81 | KDM4E (0.56) | AKR1C3AKR1C2PDE4B | |
| SCHEMBL27952336 | 0.80 | SIRT2 (0.54) | AKR1C3AKR1C2 | |
| SCHEMBL9595058 | 0.80 | AKR1C3 (1.00) | AKR1C3AKR1C2 | |
| SCHEMBL4581492 | 0.80 | HSP90AA1 (0.54) | AKR1C3AKR1C2PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1667685-B1 | QUINAZOLINE POTASSIUM CHANNEL INHIBITORS | MERCK SHARP & DOHME (US) | 2012-03-14 | — | — | EP | disclosed |
| US-7906521-B2 | Quinazoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-03-15 | — | — | US | disclosed |
| EP-1667685-A4 | QUINAZOLINE POTASSIUM CHANNEL INHIBITORS | MERCK & CO INC (US) | 2009-04-29 | — | — | EP | disclosed |
| US-20070054894-A1 | Quinazoline potassium channel inhibitors | MERCK & CO., INC. (US) | 2007-03-08 | — | — | US | disclosed |
| CN-1856310-A | Quinazoline potassium channel inhibitors | MERCK & CO INC (US) | 2006-11-01 | — | — | CN | disclosed |
| EP-1667685-A1 | QUINAZOLINE POTASSIUM CHANNEL INHIBITORS | Merck & Co., Inc. (US) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005030217-A1 | QUINAZOLINE POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054894-A1 | Quinazoline potassium channel inhibitors | KCNJ2, KCNH2, KCNH3 | AKR1C3 2614/4885AKR1C2 1933/4885PDE4B 1286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.